A committee of independent vaccine experts has made a groundbreaking decision to recommend lowering the age at which adults can receive a vaccine against respiratory syncytial virus (RSV). This move could potentially make RSV vaccines accessible to adults in their 50s who are at high risk of severe illness from the virus.
The Advisory Committee on Immunization Practices (ACIP) voted to recommend that any RSV vaccine for adults licensed by the Food and Drug Administration (FDA) for high-risk adults aged 50 to 59 should be recommended for use in that age group. If this recommendation is accepted by the Centers for Disease Control and Prevention (CDC), insurance companies will be required to cover the cost of the vaccine for eligible individuals.
The timeline for the implementation of this recommendation is uncertain. ACIP recommendations must be approved by the director of the CDC, and currently, the agency does not have a director. Susan Monarez, the acting director who was proposed as the nominee for the position, has not yet undergone Senate confirmation.
In the absence of a CDC director, legal experts suggest that Health Secretary Robert F. Kennedy Jr. could sign off on the committee’s recommendations. The CDC’s chief of staff, Matthew Buzzelli, is expected to receive the six recommendations from the committee arising from Wednesday’s meeting.
Aside from the vote on RSV vaccines, the committee also recommended the use of a new meningococcal vaccine from GSK and a chikungunya vaccine from Bavarian Nordic. They also made adjustments to a previous recommendation for another chikungunya vaccine by Valneva.
If accepted by the CDC, the vote on the use of RSV vaccines in people in their 50s would initially apply to vaccines from GSK and Pfizer. Moderna is in the process of seeking FDA approval to extend the license for its RSV vaccine to include high-risk individuals aged 50 to 59.
A cost analysis conducted by the CDC and researchers from the University of Michigan suggested that the use of these vaccines in selected members of this age group could result in cost savings. Individuals who have undergone lung transplantation, have heart failure, chronic obstructive pulmonary disease, chronic kidney disease, or severe obesity should be considered for RSV vaccination in their 50s.
Approximately 30% of U.S. adults aged 50 to 59 would qualify for the RSV vaccine, according to Michael Melgar, a CDC vaccines researcher. The current CDC recommendation for RSV vaccines states that individuals aged 75 and older should receive the vaccine, as well as high-risk individuals aged 60 to 74.
One concern regarding RSV vaccines is the potential link between the Pfizer and GSK products and an increased risk of Guillain-Barré syndrome. Another concern is the uncertainty regarding the frequency of vaccine administration and whether additional doses will provide adequate protection.
The committee also voted to recommend the use of a new chikungunya vaccine, Vimkunya, for travelers and laboratory workers who deal with the chikungunya virus. The vaccine, developed by Bavarian Nordic, is licensed for individuals aged 12 and older.
Chikungunya infection, transmitted by infected mosquitoes, causes fever, muscle, and joint pain that can be severe and long-lasting. The vaccine can be used by individuals traveling to countries experiencing chikungunya outbreaks or where the risk of transmission is high for an extended period.
The committee had previously recommended another chikungunya vaccine by Valneva for individuals aged 65 and older. However, reports of serious side effects in older adults after vaccination prompted the committee to revise this recommendation. The Advisory Committee on Immunization Practices (ACIP) recently made a recommendation regarding the use of the Valneva vaccine in people 65 and older. While the committee did not recommend against the use of the vaccine in this age group, they did advise that a precaution be taken when administering the vaccine to individuals over the age of 65.
In addition to their recommendation on the Valneva vaccine, the ACIP also suggested the use of GSK’s pentavalent vaccine to protect against meningitis, specifically the MenABCWY strain. This vaccine is recommended for individuals aged 16 to 23 who are at risk of contracting meningitis B. It is also recommended for those aged 10 and older who have underlying medical conditions that put them at increased risk of developing meningococcal disease.
The ACIP’s recommendations are important guidelines for healthcare providers and public health officials to follow when determining the best vaccination strategies for their patients. By staying up to date on the latest recommendations from organizations like the ACIP, healthcare professionals can ensure that they are providing the best possible care to their patients.
It is crucial for individuals to consult with their healthcare providers to determine the most appropriate vaccination schedule for their specific needs. By following the recommendations of organizations like the ACIP and discussing vaccination options with their healthcare providers, individuals can protect themselves and their communities from dangerous diseases like meningitis.
